Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis
Background and Aim Apolipoprotein A2 (apoA2) isoforms have been reported to undergo the aberrant processing in pancreatic cancer and pancreatic risk populations compared with that in healthy subjects. This study aimed to clarify whether apoA2 isoforms were as useful as N‐benzoyl‐p‐aminobenzoic acid...
Saved in:
Published in: | Journal of gastroenterology and hepatology Vol. 38; no. 11; pp. 1949 - 1957 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Australia
Wiley Subscription Services, Inc
01-11-2023
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Aim
Apolipoprotein A2 (apoA2) isoforms have been reported to undergo the aberrant processing in pancreatic cancer and pancreatic risk populations compared with that in healthy subjects. This study aimed to clarify whether apoA2 isoforms were as useful as N‐benzoyl‐p‐aminobenzoic acid (BT‐PABA) test for exocrine pancreatic dysfunction markers in patients with early chronic pancreatitis (ECP).
Methods
Fifty consecutive patients with functional dyspepsia with pancreatic enzyme abnormalities (FD‐P) (n = 18), with ECP (n = 20), and asymptomatic patients with pancreatic enzyme abnormalities (AP‐P) (n = 12) based on the Rome IV classification and the Japan Pancreatic Association were enrolled in this study. The enrolled patients were evaluated using endoscopic ultrasonography and endoscopic ultrasonography elastography. Five pancreatic enzymes were estimated. Pancreatic exocrine function was analyzed using the BT‐PABA test. Lighter and heavier apoA2 isoforms, AT and ATQ levels were measured by enzyme‐linked immunosorbent assay methods.
Results
There were no significant differences in clinical characteristics such as age, gender, body mass index, alcohol consumption and smoking among patients with AP‐P, FD‐P, and ECP. The BT‐PABA test and lighter apoA2 isoform, AT level in the enrolled patients had a significant correlation (P < 0.01). The BT‐PABA test in patients with ECP was significantly lower (P = 0.04) than that in AP‐P. ApoA2‐AT level in patients with ECP was lower than that in AP‐P, albeit, insignificantly. Interestingly, apo A2‐AT level was significantly (P = 0.041) associated with exocrine pancreatic insufficiency by multiple logistic regression analysis.
Conclusions
ApoA2‐AT level is a useful tool to evaluate exocrine pancreatic insufficiency in the early stage of chronic pancreatitis. |
---|---|
Bibliography: | Author contribution SA, KN, YW, MH, RK, HY, RT, KK, TA, NI, NU, AK, KI, YN, NS, KT, TT, RO, SM, NT, HY, and KH: data collection, SF: data collection, direction of experiment, writing the manuscript. Kazufumi Honda is an adviser to Toray Industries, Inc. Kazufumi Honda is an inventor with patent filings for apoA2‐i. Declaration of conflict of interest This study was supported by funding from Toray Industries, Inc. and grants from the Japan Agency for Medical Research and Development (AMED): AMED P‐CREATE [No. 21cm0106403h0006] (KH), AMED P‐PROMOTE [No. 22ama221401h0001] (KH), and AMED Practical Research for Innovative Cancer Control [Nos. 19ck0106280h0003 and 22ck0106661h0002] (KH). Financial support ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0815-9319 1440-1746 |
DOI: | 10.1111/jgh.16302 |